←Back to Expert Scholars
Translational Medicine / 转化医学Amino Acid Metabolism, Glutaminase Inhibition
Kevin Marks
PhD
🏢Calithera Biosciences (Historical)🌐USA
Vice President, Research
30
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Kevin Marks led drug discovery efforts on glutaminase inhibitors including telaglenastat for cancer indications. His work translated DeBerardinis-style glutamine biology into clinical candidates. He highlights both promise and challenges of metabolic targeted therapies.
Share:
🧪Research Fields 研究领域
glutaminase inhibitors
telaglenastat
cancer drug discovery
metabolic targeting
translational pharmacology
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Kevin Marks 的研究动态
Follow Kevin Marks's research updates
留下邮箱，当我们发布与 Kevin Marks（Calithera Biosciences (Historical)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment